Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

OncoCompass™ Target

CE Marked
Related tests:
OncoCompass™ Target is ctDNA liquid biopsy-based test for NSCLC which is upgraded to a pan-cancer test for all solid tumors. This test analyzes 168 genes that are related to the development of NSCLC and solid tumors, including all genes that have a targeted therapy that is FDA- or NMPA-approved or NCCN-recommended. It provides information with optimal clinical value for cancer patients, especially advanced-stage cancer patients who do not have accessible tissue, for various solid tumors across treatment stages, from baseline profiling, dynamic monitoring to MRD detection.
Non Small Cell Lung Cancer
ALK (Anaplastic lymphoma kinase), EGFR (Epidermal growth factor receptor), PD-L1 (Programmed death ligand 1), TMB (Tumor Mutational Burden)
Tagrisso (osimertinib)
Next-Generation Sequencing (NGS)